SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CYPB - Cypress BioScience -- Ignore unavailable to you. Want to Upgrade?

To: dwight martin who wrote (272)6/3/1998 10:29:00 AM
From: John S. Baker  Respond to of 586
 
Yes, Martin ... it *would* appear that there is room for CYPB.


And the various analysts reports I have read all are based on CYPB being used only for those patients who do not respond to the other (drug) therapies.



To: dwight martin who wrote (272)6/3/1998 11:41:00 AM
From: Jay Lowe  Read Replies (2) | Respond to of 586
 
Wow ... now *there's* a summary. I've filed it for ... looks like
I need to read that about six times.

Yes, I agree that there's room for CYPB, especially as the Prosorba
treatment is especially effective in severe, drug-resistant, cases.

I bet MuddPhudd knows or can find out some useful things about the
drugs mentioned in the article.

Thanks for the post ... great article, too.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News